In the last two decades, a vast number of analogues of myelin epitope peptides as MBP 83–98, MOG 35–55, and PLP 139–151 have been evaluated in human and animal models as potential immunotherapeutics against MS [2]. This evidence concerns the gene MOG and myeloid sarcoma.